Start Date
May 17, 2019
Primary Completion Date
September 25, 2023
Study Completion Date
September 25, 2023
IMC-C103C
Weekly IV infusions
Atezolizumab
IV infusions every 3 weeks
IMC-C103C
Weekly subcutaneous Injection
Hospital Universitario Vall d'Hebron, Barcelona
Memorial Sloan Kettering Cancer Center, New York
UPMC Cancer Center, Pittsburgh
Thomas Jefferson University Hospital, Philadelphia
Clinica Universidad Navarra, Madrid
Hospital Universitario La Paz - PPDS, Madrid
Clinica Universidad Navarra, Pamplona
Sarah Cannon Research Institute at Tennessee Oncology, Nashville
The University of Chicago Medicine & Biological Sciences, Chicago
Oklahoma University Medical Center, Oklahoma City
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
The Angeles Clinic and Research Institute, Los Angeles
University of California Davis Comprehenvise Cancer Center, Sacramento
Beatson West of Scotland Cancer Centre, Glasgow
The Clatterbridge Hospital Cancer Center, Bebington
Sarah Cannon Research Institute, London
The Christie NHS Foundation Trust, Manchester
Royal Marsden Hospital, Sutton
Lead Sponsor
Immunocore Ltd
INDUSTRY